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Summary We assayed serum HMFG2 in serial samples from 215 primary epithelial ovarian cancer patients
using an 'in-house' single determinant ELISA. 45% of patients with stage I, 54% with stage II, 61% with
stage III and 75% with stage IV disease had elevated serum HMFG2. Post-operative levels were significantly
related with residual tumour volume (P<0.005), and fell in the majority of responders, although the
association with response to first-line chemotherapy was not significant. HMFG2 had a sensitivity of 50%
specificity of 83%, accuracy of 61%, PVP of 86% and PVN of 45% for disease at second-look laparotomy.
Serial levels gave a lead time to clinical relapse in 47% of patients who responded to therapy, including one
patient with negative CA125 levels. HMFG2 paralleled CA125 in many respects, although it was elevated in
fewer patients. In a stepwise discriminant analysis, HMFG2 added to the discrimination of CA125 (r = 0.183,
P<0.005), although additional accurate information was only given in patients with advanced poorly
differentiated serous cystadenocarcinoma. Given that HMFG2 is expressed in few patients who are CA125
negative it is unlikely that it will have a significant clinical impact upon patient management.
Since its discovery by Bast et al. (1981), CA125 has become
established as a useful serological marker for monitoring
patients with epithelial ovarian cancer. However, approx-
imately 15% of patients do not express CA125 and for the
past decade tumour markers that may complement CA125
have been intensively sought (Fisken et al., 1991a). The most
promising antigenic molecule to date is polymorphic
epithelial mucin (PEM), which was originally defined by
polyclonal antisera against human milk fat globule prepara-
tions by Ceriani et al. (1982). Numerous antibodies have
been raised against different epitopes found on PEM (Taylor-
Papadimitriou et al., 1981, Kenemans et al., 1988, Hilgers et
al., 1989, Price et al., 1991).
PEM is a non-gel forming mucin that has been relatively
well characterised (for review see Hilkens, 1988). Burchell et
al. (1983) showed several intermediate-sized glycoproteins in
Western blots of cell lysates of T47D breast cancer cells,
thought to be long lived intermediates in the glycoslyation
process (Griffiths et al., 1987). PEM exhibits extensive
polymorphism, first noted at the glycoprotein level (Swallow
et al., 1986 and 1987), resulting from genetic polymorphism.
Heterogeneity in the size of the apomucin results from a
variable number of tandem repeat units in the gene (Gendler
et al., 1988) which has been mapped to band 22q of
chromosome 1 (Swallow et al., 1987). Recently, Gendler et
al. (1990) have reported the full sequence of PEM.
The monoclonal antibody to HMFG2 raised by Taylor-
Papadimitriou et al. (1981) was successfully used initially for
in vivo imaging of ovarian cancer (Epenetos et al., 1982).
Whilst many antibodies are directed to the carbohydrate
moiety or a combined carbohydrate-protein epitope, anti-
HMFG2 recognises the amino acid sequence asparagine-
threonine-arginine (Price et al., 1991). Using this antibody,
Burchell et al. (1984) originally found elevated serum
HMFG2 in 5/6 ovarian cancer patients using an immuno-
radiometric assay. Two subsequent larger studies found
elevated serum HMFG2 in 3/9 (33%) stage I patients and
18/29 (62%) patients with stages II-IV (Ward et al., 1987),
and elevated serum HMFG, using antibody designated
HMFG III C12, in 15/30 (50%) and 4/34 (12%) patients
with and without clinically evident ovarian cancer respec-
tively (Ashorn et al., 1988). In addition, Ward et al. (1987)
report HMFG2 to be a clinically useful addition to CA125 in
patients with advanced ovarian cancer.
In the largest study to date, we have assayed serum sam-
ples from 215 epithelial ovarian cancer patients using a single
determinant ELISA employing the monoclonal antibody
HMFG2 (Fisken et al., 1991b). The value ofHMFG2 alone in
monitoring epithelial ovarian cancer and in addition to
CA125 was assessed.
Materials and methods
Patients andsamples
Blood samples were collected from April 1984 to July 1989
from patients attending the Royal Infirmary and Western
General Hospital in Edinburgh. The serum was separated by
centrifugation at 1500g for 10 min at room temperature and
stored in aliquots at - 20°C until assay. The patients had a
mean age of 59 years at diagnosis (median 59 years, range
23-81 years), and were followed-up on average for 26.7
months (median 20.3 months, range 0.5-173.7 months).
HMFG2 was assayed in 880 serial serum samples from 215
epithelial ovarian cancer patients while CAl 25 was assayed
in 1,237 samples from 250 patients, including those assayed
for HMFG2 Table I shows the number of patients with each
stage and histological tumour type. The discrepancy in the
total number of patients results from assaying patients for
CA125 (n = 10) and HMFG2 (n = 6) during two different
disease stages; these patients were counted twice.
CA125 assay
CA125 was assayed using the CIS IRMA according to
manufacturer's instructions. A cut-off value of 35 Umlh' was
used, as established by Bast et al. (1983).
HMFG2 assay
(1) Preparation of HMFG2-horseradish peroxidase conjugate
Horseradish peroxidase (HRP) enzyme was conjugated to
HMFG2 IgG in a 1: 1 ratio. 5 mg HRP (Sigma Type VI) was
dissolved in 1 ml distilled H20, and oxidised by the addition
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of 0.4 ml freshly prepared 0.1 M sodium metaperiodate for
20 min at room temperature in the dark, while gently stirring
occasionally. Oxidised HRP was then dialysed overnight at
4°C with 11 1 mM acetate buffer pH 4.4, stirring continuously.
The pH was brought to pH 9.0 with 0.2 M carbonate buffer
pH 9.5. 5 mg HMFG2 MAb in 1 ml carbonate buffer pH 9.5
was added and stirred gently for 2 h at room temperature in
the dark. 0.1 ml of freshly prepared sodium borohydride
(5 mgmlV' in distilled H20) was added and incubated at 4°C
for 2 h. The conjugate was finally dialysed with phosphate
buffered saline (PBS) pH 7.4 containing 0.01% Thimerosal,
and was stored in this buffer at 4°C in the dark.
(2) Extraction and deglycosylation of HMFG2 for standard
preparation
(a) Purification ofthe milk mucin Human breast milk was
centrifuged at 10000g for 30 min to isolate the skimmed milk
fraction. HMFG was prepared from human skimmed milk
by affinity chromatography on an HMFG, sepharose column
prepared by purification of tissue culture supernatant using a
Protein A column and coupling of the purified MAb to
cyanogen bromide activated sepharose (Pharmacia) as de-
scribed by the manufacturer's instructions. Human skimmed
milk was passed in batches of 100ml through the column
followed by extensive washing with PBS pH 7.4. Bound
antigen was eluted using 0.1 M glycine pH 2.5 and the frac-
tions registering absorbance at 280 nm were pooled and
dialysed against 0.25 M acetic acid and freeze dried. Solutions
made from this material were stored at - 20°C.
(b) Deglycosylation of HMFG Purified HMFG was par-
tially deglycosylated by hydrolysis with anhydrous hydrogen
fluoride for 1 h at 4°C, as described by Mort and Lamport
(1977). Longer incubation results in complete deglycosylation
of HMFG which does not react as strongly with HMFG2
antibody.
(c) Preparation of HMFG2 standards HMFG2 standards
were prepared by the method of Burchell et al. (1987) in PBS
pH 7.4, containing 7% bovine serum albumin (BSA) and
0.01% merthiolate as preservative, to avoid interference from
HMFG normally present at varying levels in normal human
sera. HMFG concentrations were set by reference to an
original preparation isolated by Dr S. Mather (St Bar-
tholomew's Hospital, London). One mg of the freeze dried
powder was arbitrarily equal to 106 units. Deglycosylated
HMFG was calibrated against a preparation obtained from
Dr J. Taylor-Papadimitriou (ICRF, Lincoln's Inn Fields,
London) in a similar way. Aliquoted standards were stable
for at least 2 weeks at 4°C, whilst deglycosylated HMFG
kept for only 1 week at 4°C.
(3) HMFG2 assay protocol and quality assessment
All samples were assayed in duplicate. Microtitre plates
(M129B, Dynatech, Billingshurst, Kent, UK) were coated
overnight at 4°C with 50 il 5.0pgml'I HMFG2 MAb in
0.05M carbonate buffer pH 9.6. The plates were washed
three times with 100"II 0.15 M PBS pH 7.4 containing 0.05%
polyoxyethylene sorbitan monolaurate (Tween 20) (PBS/
Tween 20). 25 sl neat serum, standard, or control were
incubated with 25 ,ul PBS/Tween 20 for 30 min at 37°C in a
shaking incubator (Dynatech). The plates were washed three
times with PBS/Tween 20, and 50pl HMFG2 MAb-HRP
conjugate (see 4.7.3) at 1:1000 in PBS/Tween 20 incubated
for 30min at 37°C. After three final washes, 100 jl perox-
idase substrate: 0.04% w/v 0-phenylene-diamine and 0.02%
v/v H202 in 0.15 M citrate phosphate buffer pH 5.0 was
added. The reaction was stopped after 30 min incubation at
37°C with the addition of 50 tll 2.5 M H2SO4, and optical
density determined at 492 nm with a Titertek Multiscan
(Fisken et al., 1991b).
Control and unknown sample concentrations were inter-
polated manually from dose-response curves constructed
using standard HMFG2 preparations at the following con-
centrations: 0, 50, 100, 200, 350, and 500 Uml-'. The
coefficients of variation were calculated using two controls
(50 Umlhl and 150 Uml' ). The inter-assay CVs (n = 22) for
low and high concentrations were 6.8% and 4.9% respec-
tively, while the intra-assay CVs (n = 22) for the low and
high controls were 14.9% and 6.6% respectively. A cut-off
value of 40 Uml1' was chosen empirically to give the best
discrimination between patients with active disease and those
with no disease activity. Five per cent (6/121) of apparently
healthy blood donors had levels greater than this value.
Statistics
A database containing all the patients case histories and
serial CA125 and HMFG2 levels was developed using compu-
ting facilities at Unilever Research, Colworth Laboratories.
The F test (one way analysis of variance) was used to deter-
mine the association between post-operative residual disease
and marker levels after surgery. The Kruskal Wallis test was
used to determine the relationship with overall response to
chemotherapy, and the difference between complete and par-
tial responders determined by the Mann Whitney test. The
Wilcoxon Signed Rank test was used to determine the
difference between marker levels before and after first-line
treatment.
All parametric tests were based upon logarithmic trans-
forms of marker values. The median values quoted are back-
transforms of the mean logarithms. Non-parametric analyses
were carried out in parallel but, as they were in agreement
with the parametric analyses in all cases, the latter were
preferred as being more informative.
Tests on marker change were also applied to logarithmic
transforms and therefore correspond to absolute differences
on this scale but relative changes on the original linear scale.
Results
Percentage ofpatients with raised CA125 and HMFG2
The physio-pathological cut-offs for CA125 and HMFG2
were based upon the level of analyte below which 95% of
disease-free controls fell (Bast et al., 1983; Fisken et al.,
1991a). In both cases effectiveness was confirmed with
Receiver Operating Characteristic (ROC) plots. The propor-
tion of patients with elevated CA125 and HMFG2 increased
with advancing stage, and a higher proportion of patients
with serous tumours and adenocarcinomas had elevated
CA125 and HMFG2, see (Table I). CA125 was however
elevated in a higher proportion of patients with all disease
stages and tumour types than HMFG2.
Marker relationship with tumour burden
Table II shows mean and median levels of CA125 and
HMFG2 and the proportion of patients with elevated levels
1-4 weeks after primary laparotomy (mean 17.8 days,
median 18 days, range 3-38 days) in patients with different
amounts of residual disease. Both CA125 and HMFG2
showed a significant association with tumour burden
(P<0.0001 and P<0.005 respectively). Patients with
residual disease>2 cm had significantly higher CA125 levels
that those with <2 cm residual disease (P<0.0001).
HMFG2 was less sensitive, patients with >5 cm had
significantly higher HMFG2 levels than those with <5cm
(P<0.005). HMFG2 was unable to discriminate between
tumour burdens <5 cm.
Marker relationship with response to primary chemotherapy
Figures 1 and 2 show the changes in CA125 and HMFG2
levels respectively from pretreatment to post-treatment in
patients who received first-line chemotherapy (irrespective of
drug regime). CA125 showed a significant association with
overall response to chemotherapy (P<0.005). There was anA COMPARISON BETWEEN HMFG2 AND CA125 IN OVARIAN CANCER 1067
Table I Percentage of patients with elevated CA125 and HMFG2
No. patients with elevated marker levels (%)
Disease
characteristic CA125 (>35 Uml-') HMFG2 (>40 Uml-')
Stage
I 19/38 (50%) 17/38 (45%)
II 16/25 (64%) 13/24 (54%)
III 123/146 (84%) 70/115 (61%)
IV 50/51 (98%) 33/44 (75%)
Histology
Serous 127/151 (84%) 86/126 (68%)
Endometrioid 35/46 (76%) 19/42 (45%)
Adenocarcinomaa 17/18 (94%) 9/11 (82%)
Mucinous 15/23 (65%) 7/22 (32%)
Clear cell 11/17 (65%) 9/15 (60%)
Mixed 2/3 (67%) 0/3 ( 0%)
Unknown 2/2 (100%) 1/2 (50%)
Total 208/260 (80%) 133/221 (60%)
aAdenocarcinoma of the ovary is defined as epithelial ovarian cancer not allocated to any sub-category, usually
because of poor differentiation.
Table II Correlation with residual tumour volume
Residual No patients with elevated CA125 (Uml-') HMFG2 (Uml-')
disease CA125 HMFG2 Mean Median Mean Median
None 11/15 3/16 58 56 26 22
<2 cm 21/24 8/18 238 129 39 37
2-5 cm 14/14 2/11 472 384 22 18
> 5 cm 9/9 3/6 549 458 65 48
Gross 14/14 7/11 480 403 143 103
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Figure 1 Change in HMFG2 levels with response to first-line chemotherapy.
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Figure 2 Change in CA125 levels with response to first-line chemotherapy.
average 10-fold fall in CA125 levels in responders. Pre-
treatment (Rx) CA125 levels were significantly higher than
post-Rx levels in patients who achieved both complete
(P<0.0001) and partial (P<0.002) response. However,
CA125 response did not distinguish between complete and
partial response to chemotherapy. There was no difference
between levels before and after chemotherapy in patients
with stable or progressive disease. There was an average
two-fold fall in HMFG2 levels in responders, however, the
change in HMFG2 levels did not significantly relate to re-
sponse. In addition, there were no differences between levels
before and after chemotherapy in any response category.
Prediction ofsecond-look laparotomy outcome
Table III shows the sensitivity, specificity, accuracy, and
predictive values of positive (PVP) and negative (PVN)
CA125 and HMFG2 test results within three months of
second-look laparotomy. Seventy nine patients underwent
second-look laparotomy; 32 patients had CA125 assay and
18 patients had HMFG2 assay at this time. CA125 was
slightly more sensitive, specific, and accurate than HMFG2
for disease prior to second-look laparotomy, although neither
marker was sensitive for small volume disease. CA125 was
false negative in 4/5 (80%) and 5/14 (36%) patients with
microscopic and macroscopic disease respectively, while
HMFG2 was false negative in 1/2 (50%) and 5/10 (50%)
patients with microscopic and macroscopic disease respec-
tively.
Marker lead time to clinical relapse
Twenty patients who were in complete or partial remission
with no evaluable disease and normal CA125 and HMFG2
were followed serologically until clinical relapse. Clinical
relapse was determined either by clinical examination, CT
scan, ultrasound scan, laparotomy, X-ray or some combina-
tion of these procedures undertaken by a clinical oncologist
of consultant or senior registrar grade. HMFG2 was assayed
in 15 patients. The criterion for inclusion in both cases was
the availability of samples taken at any time between the
completion of first-line chemotherapy and clinical relapse.
Marker lead time to clinical relapse was calculated as [Date
of clinical relapse - Date of Ist marker elevation]. Table IV
shows the percentage of patients with marker lead times.
CA125 gave a mean lead time of 8.6 months (median 9.6
months, range 2.0-14.8 months), while HMFG2 gave a mean
lead time of 8.6 months (median 9.2 months, range 1.2-14.8
months). HMFG2 gave similar lead times as CA125 but in
fewer patients. HMFG2, however, gave a lead time in one
patient with stage III poorly differentiated serous disease who
had negative CA125.
Does HMFG2 add to CA125?
Stepwise discriminant analysis applied to the logarithmic
transforms of the marker values showed that HMFG2 added
Table III Prediction of second-look laparotomy outcome
CA125 HMFG2
No. patients with disease 19/32 12/18
Sensitivity 53% 50%
Specificity 92% 83%
Accuracy 69% 61%
PVP 91% 86%
PVN 57% 45%A COMPARISON BETWEEN HMFG2 AND CA125 IN OVARIAN CANCER 1069
Table IV Clinical lead time to relapse
No. patients with marker lead time
CA125 HMFG2
Stage I 1/1 0/1
II 3/3 2/3
III 7/14 5/10
IV 3/4 0/1
Histology Serous 10/14 6/10
Endometrioid 2/2 1/1
PDA 2/4 0/4
Total 14/20 (70%) 7/15 (47%)
significantly to the ability of CA125 to discriminate between
disease positivity and negativity as defined at the time of
sampling (n = 215, r = 0.183, P<0.005). This study included
all-patients and therefore all disease stages were represented.
The samples were unselected and therefore only a crude
estimate can be obtained. However, addition of HMFG2 to
CA125 increased sensitivity by 2.9%, but reduced specificity
by 17.3%, and reduced accuracy by 3%. PVN increased by
3.5% and PVP decreased by 6.5% when either CA125 or
HMFG2 were elevated compared to CA125 assay alone.
However, HMFG2 only gave additional accurate information
to CA125 in patients with stage IV poorly differentiated
serous tumours, 2/5 (40%) of whom had clinically evaluable
disease at the time of marker assay.
Discussion
Serum HMFG2 was elevated in 60% of patients overall,
while 80% had elevated CA125. Fewer patients with each
FIGO stage and histological tumour type had positive
HMFG2 than CA125 (Table I). One to four weeks after
primary surgery, 32/39 (82%) patients with less than 2 cm
residual disease and 37/37 (100%) patients with greater than
2 cm residual disease had elevated CA125 levels (Table II).
During this period, 11/34 (32.4%) patients with less than
2 cm residual disease and 12/28 (42.8%) patients with greater
than 2 cm residual disease had elevated HMFG2 levels (Table
II). Abdominal surgery is a well known cause of transient
serum CA125 elevation - which may persist for several weeks
(Van der Zee et al., 1990). The effect of surgery on HMFG2
levels is unknown, although presumably similar to CA125.
Despite surgically induced serum marker elevation, both
CA125 and HMFG2 associated significantly with residual
tumour volume. It was not possible to discriminate between
tumour masses of less than 5 cm in diameter using HMFG2
measurement, whereas CA125 levels were significantly higher
in patients with greater than 2 cm compared to less than
2 cm residual disease. Whether this reflects the relative insen-
sitivity of HMFG2 for small volume clinically undetectable
disease or poor assessment of residual tumour volume in
patients with HMFG2 assay is unclear.
CA125 associated significantly with response to first-line
chemotherapy, although there were no significant differences
between patients with complete and partial response (Figure
1). 19/23 (82.6%) patients who achieved CR and 9/13
(69.2%) patients who achieved PR had normal CA125 levels
after treatment. HMFG2 levels fell in the majority of res-
ponders, although levels were not significantly related with
response (Figure 2). 13/15 (86.7%) patients who achieved CR
and 7/9 (77.8%) patients who achieved PR had normal
HMFG2 levels after completion of first-line chemotherapy.
Consequently, both markers had poor sensitivity for disease
at second-look surgery (Table III). CA125 had a sensitivity
of 53%, similar to values quoted in the literature (Jacobs &
Bast, 1989), while HMFG2 had a sensitivity of 50% for
disease at second-look. Recently, Moscovic et al. (1991)
found the sensitivity of CA125 to be better than CT scanning
prior to second-look surgery. Second-look laparotomy re-
mains the only accurate means of determining response in
patients with clinically inevaluable disease, although the
value of this procedure is questionable (Luesley et al., 1988).
Although both CA125 and HMFG2 are insensitive for
small volume disease, both markers gave a clinical lead time
to relapse (Table IV). CA125 gave a lead time to clinical
recurrence a higher proportion of patients than HMFG2,
14/20 (70%) compared to 7/15 (47%) patients, although the
actual lead times given by both markers were similar. This
does not necessarily imply that HMFG2 has the same sen-
sitivity as CA125 for occult disease, as illustrated by the lack
of discrimination between patients with residual tumour
volumes of less than 5 cm in the immediate post-operative
period (Table II). Indeed, more frequent sampling may have
revealed different marker lead times. One patient, who pres-
ented with poorly differentiated serous stage III disease, had
false negative CA125 levels had a lead time to relapse of 4.6
months given by HMFG2 serial assay. This case is atypical;
all other patients with HMFG2 lead times also had CA125
lead times.
A previous report by Ward et al. (1987) concluded that
HMFG2 assay was a useful addition to CA125 assay in
monitoring ovarian cancer patients. Although addition of
HMFG2 could be shown to increase sensitivity while retain-
ing the specificity of CA125, they make no mention of the
proportion of symptomatic patients in their population.
Moreover, the disease prevalence was 100% in their popula-
tion as all their patients had advanced disease. In our study,
HMFG2 did add significantly to CA125 in stepwise dis-
criminant analysis, however, it only gave additional accurate
information in a few patients with poorly differentiated stage
IV serous tumours, 2/5 (40%) of whom had clinically
evaluable disease at the time of marker assay. Such patients
are unlikely to benefit from marker assay, since they are
more likely to be candidates for symptomatic palliation
rather than early therapeutic intervention. In conclusion,
HMFG2 does not perform as well as CA125 as a marker for
epithelial ovarian cancer. It is doubtful that the information
it may add to CA125 would influence clinical decision mak-
ing for the majority of patients.
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